# A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

> **NCT05759728** · PHASE1,PHASE2 · RECRUITING · sponsor: **Carina Biotech Limited** · enrollment: 45 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **BIOLOGICAL:** CNA3103: 5 x 10^7 cells
- **BIOLOGICAL:** CNA3103: 1.5 x 10^8 cells
- **BIOLOGICAL:** CNA3103: 4.5 x 10^8 cells
- **BIOLOGICAL:** CNA3103: 1.5 x 10^9 cells
- **BIOLOGICAL:** CNA3103: 2.5 x 10^7 cells
- **BIOLOGICAL:** CNA3103: 6.75 × 10^8 cells

## Key facts

- **NCT ID:** NCT05759728
- **Lead sponsor:** Carina Biotech Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759728, "A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05759728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*